InvestorsHub Logo
Followers 8
Posts 668
Boards Moderated 0
Alias Born 02/25/2013

Re: Fireman02360 post# 104271

Sunday, 05/07/2017 1:17:55 PM

Sunday, May 07, 2017 1:17:55 PM

Post# of 463356
Nice find Fireman.

FDA in hot pursuit?

“After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

"The efficacy of edaravone for the treatment of ALS was demonstrated in a six-month clinical trial conducted in Japan. In the trial, 137 participants were randomized to receive edaravone or placebo. At Week 24, individuals receiving edaravone declined less on a clinical assessment of daily functioning compared to those receiving a placebo."

"The FDA granted this drug orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases."


Wow!!! did they fill the paperwork out for them too?

I can think of some other orphan designated drugs that have shown efficacy.

Note to self: Call Eric Bastings, M.D

source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News